XML 56 R36.htm IDEA: XBRL DOCUMENT v2.4.1.9
Stock Option Plans (Tables)
 12 Months Ended
Dec. 31, 2014
Stock Option Plans [Abstract]  
Allocation of stock based compensation expense
The following table summarizes stock-based compensation expense related to employee and director stock options awards for the years ended December 31, 2014, 2013, and 2012, which was allocated as follows:
 
  
Year Ended December 31,
All stock-based compensation expense:
 
2014
  
2013
  
2012
Research and Development
 
$
1,309,703
  
$
829,938
  
$
815,052
General and Administrative
  
3,145,717
    
2,214,836
    
1,028,910
 
All stock-based compensation expense included in expenses
 
$
4,455,420
   
$
3,044,774
   
$
1,843,962
 
Schedule of weighted average assumptions to calculate fair value of stock options
The weighted-average estimated fair value of stock options granted during the years ended December 31, 2014 and 2013 was $3.43 and $4.13 per share respectively, using the Black-Scholes Merton model with the following weighted-average assumptions:

  
Year Ended
December 31,
  
2014
 
2013
Expected life (in years)
  
6.67
   
6.68
 
Risk-free interest rates
  
2.19
%
  
1.51
%
Volatility
  
83.20
%
  
95.22
%
Dividend yield
  
0
%
  
0
%
Summary of stock option activity

  
Options
Available for
Grant
  
Number of
Options
Outstanding
  
Weighted
Average
Exercise
Price
January 1, 2013
  
3,745,000
   
3,681,301
  
$
1.96
 
Granted under 2012 Plan
  
(1,585,000
)
 
  
1,585,000
   
4.13
 
Exercised
  
-
   
(20,000
)
 
  
2.30
 
Forfeited/expired under 2002 Plan
  
-
   
(524,166
)
 
  
4.01
 
Forfeited/expired under 2012 Plan
  
155,000
    
(155,000
)
 
  
4.18
 
December 31, 2013
  
2,315,000
   
4,567,135
  
$
2.71
 
Granted under 2012 Plan
  
(2,170,000
)
 
  
2,170,000
   
3.54
 
Exercised
  
-
   
(2,060,400
)
 
  
0.58
 
Forfeited/expired under 2002 Plan
  
-
   
(179,491
)
 
  
4.32
 
Forfeited/expired under 2012 Plan
  
522,918
    
(522,918
)
 
  
3.72
 
December 31, 2014
  
667,918
    
3,974,326
   
$
4.04
 
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Additional information regarding options outstanding
Additional information regarding options outstanding as of December 31, 2014 is as follows:

  
Options Outstanding
Options Exercisable
      
Range of Exercise
Prices
 
Number
Outstanding
 
Weighted Avg.
Remaining
Contractual Life
(years)
Weighted Avg.
Exercise Price
 
Number
Exercisable
 
Weighted Avg.
Exercise Price
2.52-8.58
  
3,974,326
   
5.57
  $ 
4.04
   
1,716,099
  $
4.48
 
$2.52-8.58
  
3,974,326
   
5.57
  
$
4.04
   
1,716,099
  
$
4.48
 
OncoCyte, OrthoCyte, ReCyte Therapeutics, Cell Cure Neurosciences, LifeMap and BioTime Asia [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Additional information regarding options outstanding
During 2013, BioTime’s subsidiary, LifeMap Solutions adopted a stock option plan that has substantially the same operative provisions as the BioTime 2002 Stock Option Plan. The LifeMap Sciences stock option plan authorized the sale of up to 18,667 shares of its common stock through the exercise of stock options or under restricted stock purchase agreements.

  
Subsidiary Options Outstanding
 
Options Exercisable
      
Range of Exercise
Prices
Number
Outstanding
 
Weighted Avg.
Remaining
Contractual Life (years)
Weighted Avg.
Exercise Price
Number
Exercisable
 
Weighted Avg.
Exercise Price
$0.003-$0.75
 
5,256,226
   
4.96
  
$
0.36
  
5,091,506
  
$
0.37
 
1.00-1.75
 
1,986,772
   
4.87
   
1.58
  
1,157,886
   
1.50
 
2.05-2.34
 
4,361,666
   
5.53
   
2.26
  
2,066,146
   
2.18
 
3.88-6.25
 
75,000
   
0.12
   
0.105
  
2,708
   
0.01
 
27.00-42.02
 
7,840
   
5.80
   
37.35
  
7,840
   
37.35
 
500.00
 
13,167
    
0.04
   
3.31
  
1,993
    
0.86
 
$0.003-$500.00
 
11,700,671
    
5.17
  
$
1.90
  
8,328,079
   
$
1.13